In this opening session, Bryn provided a comprehensive overview of entX’s strategy, highlighting how our core capability in radioisotope sourcing, processing and purification underpins three high-growth sectors: healthcare, space, and defence.

Key highlights from the session include:

• IsoMedica (Mines-to-Medicine): entX is addressing a critical global supply chain gap in radiopharmaceuticals by positioning itself as a Western supplier of key radioisotope precursors. With strong market demand and existing letters of intent in place, the IsoMedica facility remains on track for first commercial revenue in Q4 2026.

  
  

• Significant Market Opportunity: The radiopharmaceutical sector continues to expand rapidly, with over 200 drugs in development and growing demand for isotopes such as Thorium-228. entX is strategically positioned to become a key supplier into this emerging market.

  
  

• GenX Nuclear Battery Technology: entX’s GenX platform delivers long-life, maintenance-free power solutions for applications including remote sensors, defence systems, and space technologies. The technology already exceeds U.S. government performance targets and is progressing toward commercial deployment.

  
  

• Radioisotope Heating Units (RHU): entX’s RHU technology is designed to enable lunar and space missions to survive extreme conditions. A flight heritage mission is scheduled for later this year, representing a major commercial catalyst.

  
  

• Commercial Momentum: The business is transitioning from R&D into commercialisation, with near-term milestones including facility commissioning, contract conversion, prototype integration, and the upcoming RHU launch.

As Bryn noted, entX is approaching a pivotal inflection point, with multiple near-term catalysts expected across all three pillars over the next 12 months.

This webinar marks the first in a multi-part series designed to provide deeper insights into our business.